

2015 Pathology 2.0 group of ESTP Webinars



Tissue section-based investigative technologies

With the objective of continuous pathology education, **ESTP Pathology 2.0 group** invites you to a series of 4 webinars on Advanced Pathology Technologies during this year. The second and third webinars will focus on digital image analysis of immunohistochemistry and *in situ* hybridization and its uses to quantify biomarker expression and utilization as a multiplexing tool.

Webinar 2. Digital Image Analysis and Multiplexing of Biomarkers – Part 1

Speaker: **Famke Aeffner**, DVM, PhD, DACVP


Associate Director of Pathology; Flagship Biosciences Inc.

Moderator: **Helen Angell**, BSc, PhD

Senior Scientist, Molecular Pathology, Translational Science, Oncology iMed, AstraZeneca.

Date: **Tuesday, 28 April 2015 at 2 p.m. CET**

To register, please visit the [IFSTP website](#).




This webinar is jointly sponsored by the ESTP, IFSTP and IATP

Objectives:

- This is the first of two webinars addressing image analysis and multiplexing of IHC and/or ISH labelling in tissue sections; we strongly recommend attending both to get the full benefit. The second webinar will run in June.
- The 45 minute webinar will revisit the basic approaches of digital image analysis and it's utility to quantify biomarker expression in both IHC and CISH-stained sections. Specific aspects that will be covered include:
 - Measurable endpoints e.g. Area-based, cell-based and object-based;
 - Quality control including pre-analysis parameter control;
 - The pathologist's role in an image analysis team
- The 15 minute Q&A session will allow the participants to ask questions directly to the speaker and the moderator

Who should attend?

- Pathologists, residents and scientists working with IHC, CISH.
- Little prior knowledge of digital image analysis is required.



This webinar is jointly sponsored by the ESTP, IFSTP and IATP

Short Bio of Speaker:

Famke Aeffner, DVM, PhD, DACVP

Associate Director of Pathology, Flagship Biosciences Inc.


Dr. Aeffner graduated from the combined veterinary anatomic pathology and PhD program at The Ohio State University. Her special expertise is in the field of digital quantitative image analysis of human and laboratory animal histology specimens, infectious diseases, oncology, medical devices and animal models of human disease. Dr. Aeffner has extensive experience in biomarker assay development and interpretation of chromogenic and fluorescent immunohistochemistry, involving evaluation of tissues from discovery and efficacy studies and in retrospective analysis of clinical trial tissues.



Helen Angell, B.Sc., Ph.D.

Senior Scientist, Molecular Pathology, Oncology iMed, AstraZeneca

Dr. Helen K. Angell received a first class B.Sc. in Biochemistry from the University of Manchester, with industrial placement at MedImmune, Cambridge, and was awarded the Bioscience Horizons Young Scientist Award, 2008. She received a Ph.D. entitled 'Immune Modulation of the Tumour Microenvironment' from the University of Nottingham School of Pharmacy, funded by AstraZeneca and EPSRC. The project spanned several interdisciplinary projects, culminating in receipt of the AstraZeneca iMed Scientific Innovations Award. Dr. Angell then took a postdoctoral role with Dr. Jérôme Galon in the Laboratory of Integrative Immunology at the Cordeliers Research Centre, Paris. Here she contributed to the development and implementation of the 'Immunoscore'. Her main research focus was the characterisation and phenotyping of immune subpopulations, cytokines, chemokines and tumour alteration, associated with CRC progression, recurrence and metastasis. In January 2014 Dr. Angell joined AstraZeneca's Oncology iMed team as a senior scientist within the Molecular Pathology Group, Translational Science.



This webinar is jointly sponsored by the ESTP, IFSTP and IATP